Lexaria Bioscience Corp.
LEXXHealthcare|Biotechnology|CA
$4.50
+0.33 (+7.91%)
Tangible Book / Share
$2.42
Cash / Share
$2.19
Clinical Trials (3)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06648031 Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants | Type2diabetes | P1 | Completed | 148 | RCT, Open-label | Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide, Arm 4 - Rybelsus medication (semaglutide) alone, Arm 5- Tirzepatide |
| NCT05346562 Oral Cannabidiol Effect on Blood Pressure in Hypertensive Patients | Hypertension | P1 | Completed | 70 | RCT, Double-blind | — |
| NCT03295903 Cannabinoid Supplementation on Vascular and Cognitive Function | Diet Modification | Early P1 | Unknown | 24 | RCT, Double-blind | — |